Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.

Recs

0

Today's Top Health Care Stocks to Watch: Celgene and Rite Aid

Let's take a look at today's top stories in biotech and health care. Keep an eye out for Celgene (NASDAQ: CELG  ) and Rite Aid (NYSE: RAD  )  

Celgene shares move higher after split is announced
Celgene shareholders approved a two for one stock split yesterday at the company's annual meeting. The split will increase the number of outstanding shares from 399 million to approximately 798 million. What this means is that shareholders will receive one extra share for every share they currently own.

Is this a good move? Forward stock splits generally help increase a company's value over the long-term, as it makes the stock more affordable for a broader base of investors. With a share price presently exceeding $160 per share, for example, some retail investors are probably unwilling to invest even if they think the company still has upside potential. In short, a lower share price tends to entice more buyers over the long term. Celgene shares are up 0.58% following this news.   

Rite Aid shares falling after reporting first-quarter earnings
Shares of drugstore company Rite Aid are down over 4% in premarket this morning after posting first-quarter results. Per the release, the company reported net income of $41.4 million or $0.04 per diluted share, which is in-line with consensus estimates. Revenues also increased year over year by 2.7% to $6.47 billion, beating consensus by $3 million.

Despite earnings coming in more or less on target, investors are keying in Rite Aid's lower profitably due to higher taxes, drug costs, operating costs and reimbursement rate reductions. Specifically, profit fell by a noteworthy 55% compared to the same period a year ago. Looking ahead, management reaffirmed its 2015 guidance, with annual sales expected to come in between between $26.0 billion and $26.5 billion.  

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3000048, ~/Articles/ArticleHandler.aspx, 8/29/2015 2:28:36 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

George Budwell
gbudwell

George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.

Today's Market

updated 5 hours ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/28/2015 4:00 PM
CELG $124.04 Up +1.00 +0.81%
Celgene CAPS Rating: *****
RAD $8.24 Down +0.00 +0.00%
Rite Aid Corp CAPS Rating: ***